Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

Vista sencilla de ítem
dc.audience
dc.audience
dc.citation.titleMetformin and propranolol combination prevents cancer progression and metastasis in different breast cancer modelses
dc.creatorRico, María José
dc.creatorBaglioni, María
dc.creatorBondarenko, Maryna
dc.creatorLaluce, Nahuel Cesatti
dc.creatorRozados, Viviana R.
dc.creatorAndré, Nicolas
dc.creatorCarré, Manon
dc.creatorScharovsky, O. Graciela
dc.creatorMárquez, Mauricio Menacho
dc.date.accessioned2018-05-31T18:20:11Z
dc.date.available2018-05-31T18:20:11Z
dc.date.issued2016-12-01
dc.descriptionDiscovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.es
dc.description.filFil: Rico, María José. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentinaes
dc.description.filFil: Bondarenko, Maryna. Aix-Marseille Université. Inserm UMR_S 911. Centre de Recherche en Oncologie biologique et Oncopharmacologie. Faculté de Pharmacie; Marseille; Francees
dc.description.filFil: Laluce, Nahuel Cesatti. Instituto de Genética Experimental. Facultad de Ciencias Médicas. Universidad Nacional de Rosario; Rosario; Argentinaes
dc.description.filFil: Rozados, Viviana R. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentinaes
dc.description.filFil: André, Nicolas. Service d'Hématologie and Oncologie Pédiatrique. AP-HM. Boulevard Jan Moullin; Marseille; Francees
dc.description.filFil: Carré, Manon. Aix-Marseille Université. Inserm UMR_S 911. Centre de Recherche en Oncologie biologique et Oncopharmacologie. Faculté de Pharmacie; Marseille; Francees
dc.description.filFil: Scharovsky, Graciela Olga. Universidad Nacional de Rosario. Consejo de Investigaciones UNR, Facultad de Ciencias Médicas; Argentinaes
dc.description.filFil: Márquez, Mauricio Menacho. Instituto de Genética Experimental. Facultad de Ciencias Médicas. Universidad Nacional de Rosario; Rosario; Argentinaes
dc.description.filFil: Baglioni, María. Instituto de Genética Experimental. Facultad de Ciencias Médicas. Universidad Nacional de Rosario; Rosario; Argentinaes
dc.description.sponsorship“Agencia Nacional de Promoción Científica y Tecnológica” PICT2014-2025 and “Instituto Nacional del Cáncer” (National Cancer Institute of Argentina; Asistencia Financiera a proyectos de investigación en cáncer de origen nacional III) to MM-M, by ¨Universidad Nacional de Rosario¨ 1MED 321 to OGS, by foundations LN13 La Vie and Les Amis de Charles, as well as by ReSOP (Timone Hospital). MVB’s salary has been supported by the “Instituto Nacional del Cáncer” scholarship program. MB’s fellowship has been funded by ITMO Cancer, from the « Institut National du Cancer » (National Cancer Institute of France).es
dc.formatapplication/pdf
dc.format.extent2874-2889es
dc.identifier.issn1949-2553es
dc.identifier.urihttp://hdl.handle.net/2133/11407
dc.language.isoenges
dc.publisherRapamycin Presses
dc.relation.publisherversionhttps://doi.org/10.18632/oncotarget.13760es
dc.rightsopenAccesses
dc.rights.holderAutoreses
dc.rights.textOncotarget applies the Creative Commons Attribution 3.0 License (CC BY 3.0) to all works we publish (read the human-readable summary or the full license legal code). Under the CC BY, authors retain ownership of the copyright for their article, but authors allow anyone to download, reuse, reprint, modify, distribute, and/or copy articles in Oncotarget, so long as the original authors and source are cited.es
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/*
dc.subjectBreast canceres
dc.subjectMetronomicses
dc.subjectDrug repositioninges
dc.subjectMetformines
dc.subjectPropranololes
dc.titleMetformin and propranolol combination prevents cancer progression and metastasis in different breast cancer modelses
dc.typearticle
dc.typeartículo
dc.typepublishedVersion
dc.type.collectionarticulo
dc.type.versionpublishedVersiones

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Menacho et al 2017 Oncotarget.pdf
Tamaño:
3.11 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
3.59 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

CIUNR - Ciencias Naturales - Artículos de Revista
FCM - Instituto de Genética Experimental - Artículos